ARTICLE | Company News

Drais, Telsar Pharmaceuticals Inc., Astellas deal

April 30, 2012 7:00 AM UTC

Astellas and Drais partnered to form virtual company Telsar to develop and commercialize Astellas' ulcerative colitis (UC) compound ASP3291. Telsar will be managed by Drais' executive team. Telsar will own all rights and assets related to the melanocortin (MC) receptor agonist, which completed a Phase I trial. Telsar plans to start a Phase IIa trial, but did not provide a timeline. ...